The European Medicines Agency (EMA) has released an overview of its key recommendations for 2025 concerning the authorisation and safety monitoring of veterinary medicines.

In 2025, the EMA recommended a total of 30 veterinary medicines for marketing authorisation, marking the second consecutive year with a record-high number of approvals. This trend highlights sustained industry interest in veterinary drug development and reflects the positive impact of the Veterinary Medicines Regulation, which came into effect in January 2022 to encourage innovation.

Of the 30 medicines recommended, 16 were vaccines. Notably, seven of these vaccines were authorised under exceptional circumstances to address urgent animal health emergencies. Five vaccines were developed using biotechnological processes, underscoring the growing role of advanced technologies in veterinary medicine.

Further details are available in the veterinary medicines highlights document published on January 19.